ATE398180T1 - Verfahren und zusammensetzungen zur modifikation der bearbeitung von apolipoprotein b-mrna - Google Patents

Verfahren und zusammensetzungen zur modifikation der bearbeitung von apolipoprotein b-mrna

Info

Publication number
ATE398180T1
ATE398180T1 AT02731102T AT02731102T ATE398180T1 AT E398180 T1 ATE398180 T1 AT E398180T1 AT 02731102 T AT02731102 T AT 02731102T AT 02731102 T AT02731102 T AT 02731102T AT E398180 T1 ATE398180 T1 AT E398180T1
Authority
AT
Austria
Prior art keywords
apolipoprotein
methods
apobec
modifying
mrna
Prior art date
Application number
AT02731102T
Other languages
English (en)
Inventor
Harold Smith
Yan Yang
Mark Sowden
Original Assignee
Univ Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rochester filed Critical Univ Rochester
Application granted granted Critical
Publication of ATE398180T1 publication Critical patent/ATE398180T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
AT02731102T 2001-02-27 2002-02-26 Verfahren und zusammensetzungen zur modifikation der bearbeitung von apolipoprotein b-mrna ATE398180T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27185601P 2001-02-27 2001-02-27

Publications (1)

Publication Number Publication Date
ATE398180T1 true ATE398180T1 (de) 2008-07-15

Family

ID=23037380

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02731102T ATE398180T1 (de) 2001-02-27 2002-02-26 Verfahren und zusammensetzungen zur modifikation der bearbeitung von apolipoprotein b-mrna

Country Status (7)

Country Link
US (2) US20040115184A1 (de)
EP (1) EP1392846B1 (de)
JP (1) JP2004521625A (de)
AT (1) ATE398180T1 (de)
CA (1) CA2439472A1 (de)
DE (1) DE60227069D1 (de)
WO (1) WO2002068676A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003257181A1 (en) * 2002-08-05 2004-02-23 University Of Rochester Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
EP1670895A4 (de) * 2003-09-03 2007-11-14 Univ Rochester Cytidin-deaminase-aktivatoren, desoxycytidin-deaminase-aktivatoren, vif-antagonisten sowie screening-verfahren für moleküle davon
WO2005115410A2 (en) * 2004-05-06 2005-12-08 University Of Rochester Context dependent inhibitors of cytidine deaminases and uses thereof
EP2059122B1 (de) * 2006-08-28 2012-06-20 University of Rochester Verfahren und zusammensetzungen in verbindung mit der expression von apobec-1
US9084762B2 (en) 2008-09-30 2015-07-21 The Regents Of The University Of California T-cell immunogens derived from anti-viral proteins and methods of using same
US20140303093A1 (en) * 2011-07-12 2014-10-09 Regents Of The University Of Minnesota Micro-utrophin polypeptides and methods
WO2013066438A2 (en) 2011-07-22 2013-05-10 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9840699B2 (en) * 2013-12-12 2017-12-12 President And Fellows Of Harvard College Methods for nucleic acid editing
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US20190225955A1 (en) 2015-10-23 2019-07-25 President And Fellows Of Harvard College Evolved cas9 proteins for gene editing
IL308426A (en) 2016-08-03 2024-01-01 Harvard College Adenosine nuclear base editors and their uses
CA3033327A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
WO2018071868A1 (en) 2016-10-14 2018-04-19 President And Fellows Of Harvard College Aav delivery of nucleobase editors
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
EP3592853A1 (de) 2017-03-09 2020-01-15 President and Fellows of Harvard College Unterdrückung von schmerzen durch geneditierung
CN110914310A (zh) 2017-03-10 2020-03-24 哈佛大学的校长及成员们 胞嘧啶至鸟嘌呤碱基编辑器
SG11201908658TA (en) 2017-03-23 2019-10-30 Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
WO2019139645A2 (en) 2017-08-30 2019-07-18 President And Fellows Of Harvard College High efficiency base editors comprising gam
AU2018352592A1 (en) 2017-10-16 2020-06-04 Beam Therapeutics, Inc. Uses of adenosine base editors
WO2020191246A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
WO2021056302A1 (en) * 2019-09-26 2021-04-01 Syngenta Crop Protection Ag Methods and compositions for dna base editing
MX2022014008A (es) 2020-05-08 2023-02-09 Broad Inst Inc Métodos y composiciones para la edición simultánea de ambas cadenas de una secuencia de nucleótidos de doble cadena objetivo.
CA3219767A1 (en) * 2021-05-14 2022-11-17 Beam Therapeutics Inc. Compositions and methods for treating transthyretin amyloidosis
CN113234745B (zh) * 2021-06-11 2021-11-02 山东祥维斯生物科技股份有限公司 利用PTD-Tat实现海洋微生物低温脂肪酶基因的跨膜转导方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468022A (en) * 1994-06-14 1995-11-21 Massachusetts Institute Of Technology Sample tube identification flag
US6041253A (en) * 1995-12-18 2000-03-21 Massachusetts Institute Of Technology Effect of electric field and ultrasound for transdermal drug delivery
US5866333A (en) * 1996-03-01 1999-02-02 Regents Of The University Of California Screening methods to detect mRNA targets of editing enzymes
US5747319A (en) * 1996-07-25 1998-05-05 Incyte Pharmaceuticals, Inc. Human mRNA editing enzyme
DE69735384T2 (de) * 1996-12-20 2006-08-10 Alza Corp., Mountain View Gelzusammensetzungen und verfahren
US5804185A (en) * 1997-03-13 1998-09-08 Incyte Pharmaceuticals, Inc. RNA editing enzyme REE-2
FR2773079B1 (fr) * 1997-12-30 2002-05-17 Itzik Harosh Cible de traitement de l'atherosclerose, de l'obesite et du diabete de type ii
EP1373308B1 (de) * 2001-04-06 2006-10-25 Thomas Jefferson University Antagonist für die multimerisierung von hiv-1 vif-protein
US20040009951A1 (en) * 2002-06-13 2004-01-15 Malim Michael H DNA deamination mediates innate immunity to (retro)viral infection
AU2003257181A1 (en) * 2002-08-05 2004-02-23 University Of Rochester Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
DE602004012406T2 (de) * 2003-05-23 2009-04-30 Oregon Health & Science University, Portland Verfahren zur identifikation von inhibitoren
EP1670895A4 (de) * 2003-09-03 2007-11-14 Univ Rochester Cytidin-deaminase-aktivatoren, desoxycytidin-deaminase-aktivatoren, vif-antagonisten sowie screening-verfahren für moleküle davon

Also Published As

Publication number Publication date
EP1392846A4 (de) 2005-09-21
WO2002068676A2 (en) 2002-09-06
WO2002068676A3 (en) 2003-12-24
US20100297219A1 (en) 2010-11-25
DE60227069D1 (de) 2008-07-24
CA2439472A1 (en) 2002-09-06
JP2004521625A (ja) 2004-07-22
EP1392846A2 (de) 2004-03-03
US20040115184A1 (en) 2004-06-17
EP1392846B1 (de) 2008-06-11

Similar Documents

Publication Publication Date Title
ATE398180T1 (de) Verfahren und zusammensetzungen zur modifikation der bearbeitung von apolipoprotein b-mrna
ATE277198T1 (de) Verfahren zur in vitro evolution von proteinfunktionen
ATE346160T1 (de) Proteingerüste für antikörper-mimetika und andere bindungsproteine
ATE439592T1 (de) Proteingerüste für antikörper-nachahmer und andere bindende proteine
DE69917716D1 (de) Protein-deamiderendes Enzym, dafür kodierendes Gen, Verfahren zur Herstellung und Verwendung davon
ATE373719T1 (de) Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
ATE352617T1 (de) Lösliche polypeptidfraktionen des lag-3-proteins; verfahren zur herstellung; therapeutische zusamensetzung; antiidiotypischer antikörper
ATE330630T1 (de) Antikoagulierende humanisierte antikörper gegen faktor ix, zur verwendung in der behandlung von thrombose
ATE135371T1 (de) Mit akuter pankreatitis assoziiertes protein, mittel zur diagnose von akuter pankreatitis
DE69931946D1 (de) Zusammensetzungen und verfahren zur zubereitung von dispersionen und verfahren zur verwendung der dispersionen
ATE243753T1 (de) Mch4 und mch5, apoptotische proteasen, dafür kodierende nukleinsäure und verfahren zur verwendung
ATE309353T1 (de) Verfahren zur herstellung von rekombinanten peptiden
WO2003031598A3 (en) Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
DE69513027D1 (de) Verfahren zur bestimmung des präthrombotischen status
WO1994021800A3 (en) Protein tyrosine phosphatase ptp-s31
WO2002064840A3 (en) Methods for identifying compounds that inhibit or reduce ptp1b expression
DE602004032345D1 (de) Reagenzien und verfahren zur bildung von disulfid-bindungen und glykosylierung von proteinen
DE69835813D1 (de) Verfahren zur kultivierung von zellen und zur vermehrung von viren
ATE230414T1 (de) Mimetika von beta-faltblatt und verfahren zur verwendung davon
ATE417112T1 (de) Steigerung der immunantwort unter verwendung von zielgerichteten molekülen
DE60239450D1 (de) Verfahren zur behandlung von psoriasis unter verwendung eines il-17d antagonisten
WO2005111070A3 (en) Mucin3 egf-like domains
DE69525287D1 (de) Endotoxin-Stabilisierungsmittel, Endotoxin-Zusammensetzung und Verfahren zur Bestimmung von Endotoxin
DE60011785D1 (de) Verfahren zur herstellung von proteinen in wirtszellen unter verwendung von chaperoninen
ATE379967T1 (de) Nukleinsäuren kodierend miteinander verbundene chromo/fluoreszenzdomänen und verfahren zu ihrer verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties